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INTRODUCTION 
 
  
Organophosphporous compounds are world wide used pesticides which 
is a major threat to human population either by suicidal ingestion , accidental 
inhalation and skin contamination while spraying. Agriculture is the major 
occupation that is carried out in india. 
 
Pesticides are substances used in agriculture that are intended to control 
pests and weeds . Those can be used in chemical warfare as biological agents 
Pesticides include all our herbicide, insecticide, and disinfectant. 
 
In our country around 60% of self harm is by suicidal intend of 
poisoning. Organophosphorous  compounds are commonly used around  80% 
of our  total pesticide poisoning.  
 
In our toxicology unit of poison research centre in Rajiv Gandhi 
government General hospital, chennnai, in the year 2017 and 2018  we had 
around 234 and 246 cases of  organophosphorous coumpound poisoning and 
most of the mortality around 20 % are probably due to respirtory failure  and  
mechanical ventilatior  related complications like ventilator associated 
pneumonia , etc., 
 
 
 
 
  
 
 
AIMS AND OBJECTIVES 
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AIMS AND OBJECTIVES 
 
1. To clinically categorise the severity of organophosphorus poisoning 
from  admission till discharge  by WHO clinical severity  Paradyneia  
Organophosphorus Poisoning scoring system. 
 
2. To  correlate  clinical severity POP scoring from  admission till 
discharge with arterial blood gas interpretation values on 
Organophosphorous compound poisoning. 
 
3. To  correlate serum  acetylcholinesterase values from admission and 
serially till discharge with arterial blood gas values interpretation and to 
intervene as early as possible. 
 
4. To correlate arterial blood gas analysis  with  atropine requirement, 
duration of ventilation and hospital stay days 
 
5. To correlate arterial blood gas analysis with one or more of 
complications  like respiratory failure and the need for mechanical 
ventilation, intermediate  syndrome, acute renal shutdown, convulsion, 
arrhythmias and coma 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
 
 
Historical Background 
 
 
In 1837 Von Hofmann synthesized methyl phosphor chloride as first OP 
compound. Tetraethylpyrophosphate (TEPP), was a potent synthetic toxic OPC 
compound synthesized by Clermont in 1854. Schrader's group synthesized 
thousands of compounds, the most  popular insecticide parathion . 
 
The major threat to human community in the form of toxicity are the 
two major compounds  mainly organophosphorous and carbamate compounds .  
"Organophosphate"  includes  all our   phosphorus- containing 
insecticides , phosphate containing compounds with  P atom surrounded by 
four O atoms and  other derivatives of phosphoric and phosphonic acids such 
as phosphonates that inhibit cholinesterase. 
Some nerve agents had been produced in germany that are used in 
chemical warfare in second world war, sarin has been used in chemical 
terroristic attack at Tokyo, Japan. 
Nowadays wide range of organophosphorous compounds have  been 
used with  Biological properties  
 
Structure of  organophosphorous compound 
Organophosphorus compounds are phosphoric acid esters, otherwise 
called as phosphorous containing organic compounds in which centrally 
located phosphorous compound surrounded by 4 atoms in which one is the 
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terminal  oxygen which is double bonded  and other three are two  lipophilic 
groups (R) and a leaving group (X) that are connected by single bond . The  
"leaving group" determines  the  OPC characteristics  and  classify it  into four 
main categories, prototype compound is diflurophosphate 
 
 
 
 
Class I –If there is a nitrogen at the X position, and the OP compound  
are collectively  termed phosphorylcholines. 
Class II  - Fluorine molecule at the X position,OP compounds are called 
as fluorophosphates  
Class III – If there is an cyanide  molecule or a other  halogen the X 
position, they  are called as cyanophosphates 
Class IV -Dimethoxy or diethoxy  at the X  position containing OP 
compounds 
 
MECHANISM : 
Three groups – reversible inhibitors , carbamoylating inhibitors and 
organophosphorous compounds. 
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PHARMACODYNAMICS AND PHARMACOKINETICS 
Organophosphorous compounds absorption occurs through skin 
contamination, ingestion, inhalation or injection.  
Both pharmacokinetics and dynamics depends upon several factors : 
1. Route of administration, mode of  absorption , bioavilability 
2.Distribution to tissue sites and organs  
3. Metabolism and activation 
4. Mode of  excretion. 
Distribution is predominantly on major organs that to majority of 
amount around 50 %  in liver and kidneys. Plasma  half life  ranges from few 
minutes to few  hours, duration of symptoms is determined by property of the  
compound – lipid  solubility, oxon activation , stability of compound and 
acetylcholinesterase bond and aging.. Metabolism occurs by oxidation or 
esterase hydrolysis.Around  80% ofcompound are excreted within 48 hours of  
exposure  through  urine and stools.lipid soluble agents  may take several days 
to weeks to manifest symptoms and signs  because the substance may be get 
out of the fat at later stages, whereas other compounds it takes a mean of 
around 8 hours. 
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CLASSIFICATION OF ORGANOPHOSPHORUS AND CARBAMATE 
COMPOUNDS 
A.HIGHLY TOXIC 
Disulfoton 
Isoflurophate 
Monochrotophos 
Tetraethylpyrophosphate 
Dicrotophos 
Dichlorovas 
Chlormephos 
Methyl Parathion 
 
B.MODERATELY TOXIC 
Cyanophos 
Dichlorphos 
Chlorpyrifos 
Triazophos 
EPBP 
Profenofos 
Formothion 
Diazinon 
Fenthion 
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C.LEAST TOXIC 
Bromophos 
Propylthiopyrophosphate  
Quinalphos 
Temephos 
Malathion 
Dimethoate 
Tetrachlorvinphos  
Prophenophos 
 
CARBAMATES 
Carbaryl  
Propoxur  
 
MECHANISM OF ACTION 
 Neurotransmission in sympathetic , parasympathetic ganglia is mainly 
by acetylcholine. The place were at other sites acetylcholine acts  as an 
neurotransmitter are postganglionic sympathetic fibres and parasympathetic 
nerve  and also skeletal muscle neuromuscular junction , sweat gland. when 
nerve  axon potential  depolarises neuromuscular junction, vesicles containing  
neurotransmittrers such as ACh fuse with nerve terminals, releasing ACh into 
the synapse or neuro muscular junction. Acetylcholine acts both at muscarnic 
and nicotinic receptors. 
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Nicotinic receptors exists at skeletal neuromuscular junction, autonomic 
ganglia , adrenal medulla and in the central nervous system , whereas 
Muscarnic receptors are present in all organs , tissues , and all cell types 
Certains subtypes predominate in certain areas as like M2  in  Heart and M3 in 
Bladder. 
Acetylcholine receptor consists 5 glycosylated protein subunit 2 alpha, 
beta, delta and epsilon subunit ACh  binds to  either  postsynaptic muscarnic or 
nicotinic receptors followed by a G protein coupled action at ligand gated 
muscarnic receptor leading to activation of   ionic currents on nerve cells, that  
alters  flow of Na+ , K+ , Ca+ across  postsynaptic cell membrane, resulting in 
propagation  of the action potential. 
Acetylcholinesterase belongs to carboxylesterase family which is found 
in two forms: 
1. True acetyl cholinesterase – found in tissues and red blood cell 
membranes 
2. Pseudocholinesterase – found in serum and liver. 
 
Organophosphates are anticholinesterse that  phosphorylates esteratic 
site of  acetyl cholinesterase enzyme similar to acetylcholine  thus by causing 
accumulation of actylcholine in the synapse or NMJ . The reactivation of 
enzyme may occur spontaneously . 
Active region of acetylcholinesterase contains one anionic site and an 
esteratic site, phosphorylated enzymes by reversible inhibitors that react 
extreme slow with water because of phosphorylation. 
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Aging is a process by which phosphorylated enzyme becomes resistant  
hydrolysis hence pralidoxime should be used within 24 hours 
Organophosphorous compound binds to a hydroxyl group of AChE  
enzyme. Acetylcholinesterase splits of leaving (X) group of OPC poisoning 
which forms a reversible bond thus by inactivating enzyme. 
Pralidoxime or obidoxime, speed up the rate of reactivation. 
Spontaneous reactivation is faster in dimethoxy OPc. Half-life for spontaneous 
reactivation of human AChE inhibited by dimethoxyOPc is 0.7-0.8 
hour,diethoxy inhibition  is 30-60 hour ,this means that patients who present to 
a hospital 4 hours after  poisoning with a dimethoxy OPc , thus after 14 hours 
nearly half of their total body acetylcholine are resistant to hydrolysis, hence  
the patients might  be  completely  refractory to oxime therapy after fourteen 
hours  
Normal physiological reaction is a rapid one, in which acetylcholine 
acetylates  acetylcholinesterase enzyme which inturn  forms  acetylcholine- 
enzyme complex. The acetylated enzyme undergoes hydrolysis and forms 
acetic acid and choline releasing the free enzyme. Acetylated enzyme reacts 
with water extreme rapidly and the esteratic site is freed in fraction of seconds, 
whereas In organophosphorus compounds poisoning, it phosphorylates enzyme 
complex  instead of acetylation,phosphorylation makes the reaction extremely 
slower one to convert it into a free enzyme. 
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 Non-availability of free enzyme leads to excess acetylcholine in the 
synapse and neuromuscular junction leading onto the toxic clinical 
consequences. Oximes accelerate the conversion of phosphorylated enzyme to 
free enzyme.        
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Ach + AchE------Ach-Enzyme complex 
 
 
       Acetylated                              Phosphorylated  
enzyme              enzyme 
                    OPC Very slow  
 
 
Rapid     Rapid with oximes 
 
                            Acetic acid +Choline + Free enzyme 
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CLINICAL FEATURES 
Symptoms and signs of organophosphorus poisoning: 
Both Muscarinic and Nicotinic manifestations 
GASTRO-INTESTINAL 
Anorexia / Nausea / vomiting 
Abdominal cramps 
Excessive  salivation 
Loose stools / Tenesmus 
Involuntary defecation  
 
CARDIO-VASCULAR 
Hypotension / Low BP /  Hypertension 
Bradycardia /  Tachycardia 
Arrythmias  
 
RESPIRATORY 
Running nose 
Bronchorrhea 
Hyperaemia of the upper respiratory tract 
Wheezing due to bronchoconstriction 
Respiratory paralysis 
 
GENITO URINARY 
Urinary incontinence/ involuntary urination  
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EYES 
Conjunctival hyperaemia / congestion on local contamination  
Ocular pain 
    Excessive  Lacrimation 
Miosis may not be evident due to sympathetic discharge 
 
GLANDS 
Salivation 
Localised Sweating initially later on excessively 
 
MUSCULO-SKELETAL 
Weakness 
Muscle  Fasciculation /Twitching might be scatterd  
Cramps 
Generalised weaknaess / Paralysis 
   
CENTRAL NERVOUS SYSTEM MANIFESTATIONS 
Anxiety 
Confusion /  Ataxia 
Generalised Convulsions 
Slurred speech / dysarthria 
Insomnia 
Tremors 
Coma 
Deep tendon reflexes will be absent 
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Respiratory and circulatory  depression 
  Cheyne – Stokes respiration 
 
The toxic  manifestations of  organophosphorus compounds depend on 
the type of compound, quantum of exposure, mode of administration, rate and 
amount of systemic absorption. 
 
Gastrointestinal manifestations: 
Symptoms of anorexia , vomiting, loose stools , involuntary defecation  
and abdominal cramps are first to occur after oral ingestion. 
 
Pulmonary  manifestations: 
Excessive secretions due to muscarinic action  cause obstruction of 
airways. Respiratory muscles and oropharyngeal muscles become paralysed  
due to nicotinic effects leading on to obstruction of  upper airways and 
aspiration of gastric contents. Cardiopulmonary  arrest occurs mainly due to 
depression of central nervous system.. 
Death is often due to respiratory secretions , inadequate ventilation and   
respiratory failure. Early respiratory failure during acute cholinergic crisis is 
unclear but likely to involve depression of central respiratory drive in ventral 
medulla leading to Respiratory failure, respiratory muscle weakness and 
pulmonary effects (bronchospasm and bronchorrhoea ) 
Bronchial secretions which overwhelm pulmonary function and lead to 
death often characterised as drowning on dry land. OPC poisoning produces 
cholinergic crisis by inhibition of acetylcholinesterase In central and peripheral 
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nervous system leading to wide range of clinical effects including central 
apnea, pulmonary bronchoconstriction and secretions, seizures and muscle 
weakness, all these results in flaccid and paralysed muscles which ultimately 
lead to respiratory failure and acid base disturbances. 
Excess synaptic acetylcholine stimulates muscarinic receptors and then 
depresses or paralyses the nicotinic receptors which may cause cause carbon 
dioxide retention  
Cardiovascular system manifestations: 
Mechanisms may be due to direct toxic effects on the myocardium or 
due to other contributory factors like hemodynamic abnormalities, severe 
metabolic acidosis, hypoxia,electrolyte imbalance /disturbances or even with 
high doses of atropine. 
They might cause  most dreaded complications or even many times fatal 
leading to death. 
Neurological manifestations: 
Neuro muscular weakness or respiratory paralysis might lead to 
intermediate syndrome or prolonged days of ventilation leading to ventilation 
associated complications. 
Type I paralysis or acute cholinergic crisis : 
It is seen in initial phase of exposure which present with  scattered 
muscle fasciculation, paralysis, cramps & respiratory paralysis leading to 
mechanical ventilation. This phase usually passes off within 2 – 3 days. 
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Myonecrosis have been described in this phase and leads to increased serum 
levels of  creatine kinase muscle fraction CK-MM 
Type II paralysis or Intermediate syndrome : 
It usually develops within 1 – 4 days of exposure. The probable 
mechanisms postulated are  
a. Variants in susceptibility to cholinergic receptors 
b. Muscle necrosis 
c. Inhibition of AchE for long time 
d. Inadequate therapy with oximes 
e. Muscle weakness due to oxidative stress 
Weakness of  neck flexors even associated with head drooping is seen in 
this type of paralysis. 
Muscles of inspiration and expiration , proximal weakness of both upper 
and lower  limbs  and oculomotor  cranial nerves like third, fourth and sixth 
with distal muscles sparing. This  persists for a period of  4 – 18 days and even 
may require mechanical ventilatiory support. 
 
Type III paralysis or organophosphate induced delayed 
polyneuropathy (OPIDP) 
This persists for  a period of  1 to 3 weeks  after exposure which is 
usually rare toxicity due degeneration of distal axons of both central and 
peripheral nervous system due to distal motor axonopathy associated with 
cramping muscle pain in lower limb , paraesthesias and numbness, wrist drop 
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and foot drop with sparing of cranial nerves and ANS . There will be  persistent 
deficits and areflexia. 
Chronic Organophosphate induced neuropsychiatric disorder(COPIND) 
It is one of the rare phenomenon which occurs following  acute exposure 
to heavy doses of organophosphorus compounds. It produces long term effect 
with presenting features of mood liability, suicidal thoughts, irritability, 
attention deficit , disorientation, memory disturbances, delirium, schizophrenia, 
dystonic reactions, psychosis,cog-wheel rigidity. This could be attributed to the 
due to inhibition of acetylcholinesterase  in extrapyramidal system 
Immunological alterations: 
Organophosphorous compounds either by direct acetylcholine action or 
by metabolised products of OP compounds cause immune suppression leading 
to decreased chemotaxis of  neutrophils. 
It may lead on to autoimmune reactions and can cause decreased 
response for vaccines. They are more prone for recurrent viral infections, 
Endocrine manifestations: 
There may be increased  hormone release due to Increase acetylcholine 
acting on nicotinic receptors of brain producing excessive ACTH  
(Adrenocorticotrophic hormone, Antidiuretic hormone or Vasopressin, 
prolactin. Non-ketotic hyperglycemia associated with excess glucose in urine 
(glycosuria) and thyroxine production may be decreased.  
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CLINICAL SEVERITY SCORING: 
Clinical severity scoring  that are used  in organophosphorus poisoning. 
are 
1.Peradeniya Organophosphorus Poisoning (POP) scale 
  2.Poisoning Severity Scale (PSS)  
3. Modified Dreisbach Clinical Criteria 
 
The Peradeniya Organophosphorus Poisoning scale 
  score 
pupil size   
 >2mm(mydriatic) 0 
 <2mm 1 
 Pin point (miotic) 2 
Respiratory rate   
 <20/bpm 0 
 >20/bpm 1 
 >20/bpm tachypnea with central cyanosis 2 
Heart rate   
 >60/min 0 
 41 – 60/min 1 
 <40/min (Bradycardia) 2 
Fasciculation   
Twitching None 0 
 Present, generalized / continuous 1 
 Both generalized and continuous 2 
Conscious level   
   
 Conscious and rationale 0 
 Impaired response to verbal   stimuli 1 
 No response to verbal stimuli 2 
Convulsions   
 Absent 0 
 Present 1 
 
Note : 0 – 3 Mild Poisoning Score ; 4 – 7 Moderate Poisoning Score; 
 8 – 11 Severe Poisoning Score 
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DIAGNOSTIC MODALITIEs : 
I. Enzyme Levels: 
1.Cholinesterase: 
Reduction of RBC cholinesterase levels occurs in organophosphorous 
compounds poisoning. 
CNS acetylcholine levels are better expressed by RBC cholinesterase 
levels rather than plasma cholinesterase.  False positive results may be seen in  
pernicious anemia, hemoglobinopathies and with antimalarial drugs usage.  
In organophosphorus poisoning  serum  cholinesterase levels will be  
less than  5000 IU/L . .It can be raised during pregnancy and infections. Low  
levels can be seen in liver disorders, hypoproiteinemia,  succinylcholine, 
codeine, morphine drug usage  etc., because it is an acute phase reactant 
produced in liver. 
2.Creatine kinase: 
Creatine kinase is expressed by various tissues like skeletal muscles, 
heart, brain, retina, hair  and smooth muscle that  catalyses the conversion of 
creatine to phosphocreatine by consuming ATP to form ADP. 
It  lies at two places within the cell 
1. In  Mitochondria 
      2. In  Cytoplasm → 3 isoenzymes    
      CK-BB →  Brain 
      CK-MM → Skeletal muscles 
      CK-MB → Heart 
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Serum normal range of  creatine kinase  60 -400 IU/L. 
In acute organophosphorus poisoning, serum CK levels are  elevated  in 
both acute cholinergic phase and intermediate syndrome due to myonecrosis , 
but not specific. 
3. Other enzymes: 
SGOT/AST, LDH, amylase, lipase may be elevated . 
II. Arterial Blood gas analysis-  Eventhough intubation and need for  
mechanical ventilation can be assessed clinically, ABG interpretation is 
much needed to assess severity of presentation, prognosis, need for ventilation 
and clinical outcome. 
Interpretation- many parameters are expressed in ABG like PH ,PaO2 , 
PaCo2 , Hco3- , anion gap , Na+ , k+ , cl-  
PH , Hco3- , PaCo2 is the three main paremetrs needed to tell  whether it 
is a simple or complex acid base disorder  and whether it is a metabolic or 
respiratory disorder. 
Normal values – PH (7.35 – 7.45) , PaCO2 ( 35-45 ) , Hco3- (22 - 26) 
Simple acid base disorders -  
Metabolic acidosis – decreased PH and bicarbonate 
Metabolic alkalosis – increased PH and bicarbonate 
Respiratory acidosis – decreased PH and increased Paco2 
Respiratory alkalosis – increased PH and decreased Paco2 
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Mixed acid base disorders  
Metabolic acid base disturbances with respiratory compensation or 
Respiratory acid base disorder with metabolic compensation 
III. Aspiration of gastric contents and analysis in blood –  
For estimation of organophosphate compounds. 
IV. Renal Function Test: 
Increased serum creatinine and blood urea nitrogen. Electrolyte 
imbalance - Hypokalemia / Hyperkalemia 
V. Complete Blood count  
Increased total leucocyte count  and hematocrit  due to dehydration 
VI. Arterial Blood Gas analysis  
Respiratory alkalosis, Respiratory acidosis, Metabolic acidosis & 
alkalosis 
VII. Chest X Ray  
Evidence of aspiration pneumoniitis, bat wing appearance or features 
suggestive of pulmonary edema 
VIII. Electrocardiogram  
P-R interval, Q-T interval can be prolonged with elevated S-T segment , 
sinus brady/tachycardia, ventricular tachycardia, ventricular fibrillation. 
There are three phases of cardiotoxicity described by Ludomirsky et al. 
Phase I – Increased heart rate probably due to sympathetic drive which is for 
brief period  
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Phase II -  A-V conduction abnormalities probably A-V block due to 
prolonged parasympathetic stimulation 
Phase III - QT prolongation, Torsades de pointes, VT/VF 
IX. Nerve Conduction Study : 
Decremental response seen with single stimulus when repetitive firing is          
done. 
X. Serum Magnesium 
Hypomagnesemia is seen with acute organophosphorous poisoning, the  
mechanisms postulated are   
Ryles tube suction when done for long period 
Diarrhoea for a prolong period or when it is severe  
Underlying illness like chronic alcoholic , decreased oral intake or 
starvation, diabetes, hyperthyroidism, end stage renal disease 
CARDIAC 
Arrythmias  
Hypertension 
NEUROMUSCULAR 
Seizures 
Muscle cramps, numbness , paraesthesias 
Paralysis 
Acute organic brain syndrome 
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Studies relating to correlation of arterial blood gas analysis in  
organophosphorous compounds 
1. Study of acid base imbalance in organophosphorous poisoning patients    
Conducted at  Dr.S.C. Government medical college, Vishnupuri, 
Nanded , Maharastra , India by Anjali Pergulwar et al,  employing 50 
patients of acute organophosphorous compounds . 
2. A  study on acid base interpretation can be the  predictor of outcome 
among patients with acute organophosphate poisoning before 
hospitalisation by Jiung –Hsiun Liu  et al. 
3. Correlation of serum cholinesterase level, clinical score at presentation 
and severity of organophosphorous poisoning study done by  S Rehiman 
et al 
MANAGEMENT 
General Care 
* Check airway, breathing and circulation. 
* Place the patient in left lateral position with minimal foot end elevation to    
prevent aspiration. 
* Supplement high  oxygen flow and intubate if needed. 
* Start IV fluids of 0.9% Isotonic Saline  to keep systolic blood pressure of   
more than 90 mmHg. 
* Decontamination  of skin Remove the clothes, clean the patient with water 
and soap 
* Decontamination of eyes - Irrigate the eyes with normal saline, if there is 
ocular exposure. 
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• Gastric lavage to prevent gut absortion and aspirate as much as possible. 
* Insert Ryles tube and start lavage within an hour of ingestion Clean tap water 
or normal saline in  a hospital setting can be used , no dwell period is needed, 
stop lavage once the vomitus or aspirate becomes clear 
Activated charcoal 
It prevents absorption of organophosphorous compounds from stomach 
and   intestine and redues its expandable property. 
1 gram / kilogram  of activated charcoal in multiple doses  every 2 – 4 
hrs for 24 – 48 hours given through Ryle’s tube and  is contraindicated with 
paralytic  ileus or with intestinal obstruction. 
ICU care, to monitor: 
• Heart rate 
•  Pulse rate – to look for bradycardia 
• Blood Pressure – can be hyperntension or hypotension 
• Respiratory rate - tachypnea 
• Temperature- cold peripheries 
• Urine output 
•  Scattered Fasciculation / Twitching  
• Arterial oxygenation / saturation (SPO2) 
• Pupillary size to look for miosis 
• Lung signs- like wheeze or rhonchi 
• Electrocardiogram – P-R interval , Q-T interval prolongation 
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Atropine 
Atropine is the anticholinergic  agent of choice started with  dose of   
2 to 5 mg rapid intravenous bolus every 10 minutes till the development of 
signs of atropinisation like: 
Dry axilla without secretions 
Heart rate >80/min 
Clear lungs without any added sounds 
No more miotic pupils 
Systolic BP >80mmHg 
Double the  dose, if the parameters are not achieved, till adequate 
atropinisation. 
Infusion of  10 – 20% of bolus dose given to maintain atropinisation  in 
100 ml of normal saline and  assess  every 15 minutes. 
The dose of atropine should be decreased  hourly for the next 24 hours. 
Watch for atropine toxicity like delirium, confusion, urinary retention, ileus, 
pyrexia  and tachycardia. 
PRALIDOXIME (P2AM): 
It  reactivates  the acetylcholinesterase enzyme. It has three main 
actions. 
1.It  converts directly  the organophosphate compound to an inert 
substance. 
2. It protects acetylcholinesterase  enzyme from further inhibition. 
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3.  It reactivaties  alkyl phosphorylated acetylcholinesterase enzyme to 
free and active one by reactivation.  
Initial loading dose is 30 mg/kg(children 20mg /kg ) IV  bolus in 
infusion  followed by 8 mg/kg/hr for next 48 hours . 1 – 2 gm IV tds for next 5 
day should be given as infusion  in 100 – 200 ml of Normal Saline over an 
hour. Pralidoxime does not penetrate central nervous system and causes 
reactivation of skeletal muscle AchE than at autonomic sites. 
Start pralidoxime as early as possible since after 12 hours OP –enzyme 
complex  becomes resistant to hydrolysis. 
Maximum dose 12 gram in first 24 hours and titrate the dose according 
to clinical response. 
High doses or accumulation of oximes inhibit AchE and cause  
neuromuscular blockade, increased diastolic blood pressure and seizures, etc., 
Pralidoxime action is most marked at nicotinic receptor at neuromuscular 
junction. Drug should be started early before permanent binding of op 
compound to acetylcholinesterase enzyme. 
IV Magnesium Sulfate 
Intravenous magnesium sulphate is found to be beneficial  in 
organophosphorus poisoning. Mechanisms postulated  are: 
1.It reduces acetylcholine release from presynaptic terminals by 
blocking ligand gated calcium channels. 
2.Membrane stabilization of ventricular muscle cell which  prevents   
arrhythmias 
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3. Hydrolysis is increased in some pesticides. 
Sodium bicarbonate 
Sodium bicarbonate will increase the blood pH, bicarbonate levels, 
Various studies have shown it reduces mortality and morbidity that  is 
independent of correction of acidosis. 
Seizures 
Treated  with IV  sedatives belonging to benzodiazepine group 
diazepam 10 – 20 mg IV or Lorazepam 4 mg IV. 
Atropine induced  delirium 
Treated with IV  short acting benzodiazepine like midazolam  0.1 mg/kg 
or diazepam 10 – 20 mg IV. 
Mechanical ventilation 
Intubation and mechanical ventilation is much needed in respiratory 
paralysis or central apnea leading to respiratory failure. 
THERAPIES UNDER TRIAL 
Organophosphorus hydrolases 
Isolated from Pseudomonas organism  which clears organophosphorous  
compound thus reducing the blood and tissue concentration. 
* N.Methyl / D-Aspartate (NMDA)  receptor antagonists 
*Gancyclidine reduces neuronal cell death, improves electroencephalogram 
and  clinical recovery. 
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Butrylcholinesterase replacement therapy 
This is accentuated by administration of fresh frozen plasma and 
plasmaparesis which increases the enzyme levels  in the blood and neutralize 
the organophosphorus compounds. 
α-2 adrenergic receptor agonists 
Clonidine inhibits  acetylcholine release  from presynaptic terminals of 
neuromuscular junctions. 
Extracorporeal clearance  
It will be beneficial for some non-fat soluble organophsphorus 
compounds. 
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PREVENTION AND EDUCATION 
 
Improved regulations of pesticides availability and modifications of 
packaging of pesticides may all help reduced the use of organophosphates 
compounds as poison. Proper and adequate education to public, regular training 
of health care professionals, establishment of poison information centres will 
reduce morbidity and mortality related to OPC compound poisoning. 
Accidental poisoning can be prevented by keeping the insecticides out of reach 
to children.  
Proper protective universal precautions should be taken by agricultural 
workers while spraying pesticide or insecticide to prevent accidental inhalation 
or contamination . Pesticide poisoning is more common among  rural areas 
because of agricultural usage. Pesticide poisoning contributes more than 60%  
of cases in our toxicology ICU , Poison research centre and carries the 
mortality of around 19% (case register 2017 – 18).  
  
  
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
This study was conducted in our toxicology unit, poison research centre, 
Institute of Internal Medicine, Rajiv Gandhi Government General Hospital, 
Chennai. It was a cross sectional prospective study done during the period from 
August  2017to January 2018. 
50 patients, admitted as a case of acute organophosphorus poisoning 
with exposure within 24 hours irrespective of route of exposure, age and sex 
were selected and subjected for study with the consent. 
Exclusion Criteria 
1. Other pesticide poisoning. 
2. Other co morbities causing acid base disturbances like end stage renal  
    disease, Chronic lung disease, diabetes causing acidosis  
3. Mixed poisoning. 
  4. Consumption of poison with alcohol . 
Peradeniya Organophosphorus Poisoning scales were applied to patients  
assesed clinically and classified according to severity 
They were subjected to basic  blood investigations like renal function 
test including random blood sugar , serum urea and creatinine, liver function 
test, serum acetylcholinesterase, ECG  
They also have been subjected to estimation of arterial blood gas 
analysis on admission ,serially, and time of discharge.  
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Laborotory investigations and the methods employed 
1. Serum Cholinesterase : Kinetic Calorimetric method 
 2. Arterial blood gas estimation 
 
Clinical severity by POP scoring were correlated with arterial blood gas 
analysis and serum cholinesterase levels from admission till discharge or death 
serially. Patients are treated with atropine, pralidoxime, benzodiazeoines if 
needed, intubation and mechanical ventilation with our routine protocol with 
intensive care monitoring of heart rate, pulse rate, blood pressure, arterial 
oxygenation by saturation, urine output, renal parameters and liver enzymes 
and electrocardiogram. Need for Intubation and Mechanical ventilation is 
assessed clinically, arterial blood gas estimation is correlated with requirement 
of atropine dose, need for mechanical ventilation, acute renal failure, 
intermediate syndrome, convulsions and coma. 
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STATISTICAL METHODS 
 
              The data was analysed using SPSS software. Pearsons correlation 
coefficient and p value were calculated to find the statistical significance. 
Variables were considered to be significant if p value < 0.05. 
Statistical analysis was done using SPSS software. The following 
statistical methods have been employed for analysis: 
o Chi-square test 
o  Paired t-test  
o Unpaired student t-test 
o Pearson coefficient 
o Analysis of variance (ANOVA) 
 
  
  
 
 
 
OBSERVATION AND RESULTS 
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OBSERVATION AND RESULTS 
 
RESULTS 
DESCRIPTION OF STUDY POPULATION  
GRAPH -I AGE  DISTRIBUTION 
 
 
In our study population the majority forms between 20 – 30 years of 
age, next is 30-40 years and 41-50 years of age 
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TABLE-I  SHOWING AGE DISTRIBUTION 
Age Categories Frequency Percent 
<= 20 years 6 12.0 
21 - 30 years 18 36.0 
31 - 40 years 10 20.0 
41 - 50 years 10 20.0 
51 - 60 years 3 6.0 
61 - 70 years 3 6.0 
Total 50 100.0 
 
Totally 38 patiens of our study population are under 50 years of age. 
 
 
 
 
 
 
 
 GRAPH-II Distribution of Sex of the subjects in the study 
 
In our study population male population  predominates with 72%
 Frequency
 
MALE 
FEMALE 
Total 
 
 
FEMALE, 1
37 
population
 
TABLE-II 
 Percent Valid Percent Cumulative Percent
36 72.0 72.0 
14 28.0 28.0 
50 100.0 100.0 100.0
MALE, 36
4
 
 
 
 
72.0 
28.0 
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TABLE & GRAPH III  
Showing Distribution of occupation of the subjects in the study population 
 
Agriculture make only 28 %in our study population . Non – Agriculture 
by occupation predominates. 
In our study population all individuals were exposed to 
organophosphorous  compounds by ingestion only . 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
 
AGRICULTURAL 14 28.0 28.0 28.0 
NON-  
AGRICULTURAL 36 72.0 72.0 100.0 
Total 50 100.0 100.0  
 
 
14
36
0 5 10 15 20 25 30 35 40
AGRICULTURAL
NON- AGRICULTURAL
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Graph & Table - IV Distribution of toxicity of OPC with the quantity 
ingested by the subjects in the study population 
 
 
 
In our study population most of them consumed moderately toxic 
compounds that to maximum of less than 50 ml quantity. 
 
 
 
 
 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
 
<= 50 ml 24 48.0 48.0 48.0 
51 - 100 ml 17 34.0 34.0 82.0 
> 100 ml 9 18.0 18.0 100.0 
Total 50 100.0 100.0  
6
14
4
1
5
11
0
3
6
0
2
4
6
8
10
12
14
16
Mild toxic Moderately toxic Highly Toxic
<= 50 ml
51 - 100 ml
> 100 ml
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TABLE IV - I  
 
 
There is a positive correlation found between the amount of exposure to 
compounds and mean duration of symptoms as well as it can be done with 
outcome. 
 
  
Quantity of 
OPC 
N 
Mean duration 
of symptoms 
(days) 
Std. 
Deviation 
p value by 
ANOVA 
<= 50 ml 24 4.29 3.747 
0.071 
51 - 100 ml 17 6.24 4.630 
> 100 ml 9 7.89 4.076 
Total 50 5.60 4.271 
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Table & Graph –V Distribution of toxicity of OPC ingested by the subjects 
in the study population 
 
 
 
 
In  our study population 14 % consumed least toxic compounds, 42% 
consumed  highly toxic and 44% consumed  moderately toxic compounds 
 
 
Toxicity of OPC 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
Mild toxic 7 14.0 14.0 14.0 
Moderately toxic 22 44.0 44.0 58.0 
Highly Toxic 21 42.0 42.0 100.0 
Total 50 100.0 100.0  
7
22
21
0
5
10
15
20
25
Mild toxic Moderately toxic Highly Toxic
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Table-VI 
Toxicity of OPC N 
Mean duration of 
symptoms (days) 
Std. 
Deviation 
p value by 
ANOVA 
Mild toxic 7 5.57 4.577 
0.956 
Moderately toxic 22 5.41 5.011 
Highly Toxic 21 5.81 3.459 
Total 50 5.60 4.271 
 
There is no correlation found between the type / toxicity of compounds 
with mean duration of symptoms. 
There is a correlation found between level of toxicity of compounds 
with clinical severity  and also between quantum of exposure and clinical 
Severity scoring. 
In our study population patients consumed mild toxic compounds had 
only mild to moderate severity scoring whereas in moderately toxic compound 
ingested patient had equal clinical soring of mild to severe , patients consumed 
highly toxic compounds had around 76 % of severe POP scoring. 
In our study population patients who have consumed more than 100 ml 
of Compound  had, only severe clinical POP scoring from admission till 
discharge  or death. 
The severity of poisoning makes the patients seeking health care earlier 
and there  is a significant correlation. 
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Table –VII Comparison between Clinical severity scoring  and toxicity  /
  quantum of exposure of compounds 
 
Toxicity of 
OPC 
POP Score categories P value by 
Chi sq test Mild Moderate Severe 
Mild toxic 5 (71.42%) 2 (28.57%) 0 (0%) 
0.001 
Moderately 
toxic 7 (31.81%) 7 (31.81%) 8 (36.36%) 
Highly 
Toxic 1 (4.76%) 4 (19.04%) 16 (76.19%) 
Total 13 (26%) 13 (26%) 24 (48%) 
Quantity of 
OPC 
POP Score categories P value by 
chi sq test Mild Moderate Severe 
<= 50 ml 12 (50%) 11 (45.83%) 1 (4.16%) 
<0.001 
51 - 100 ml 1 (5.88%) 2 (11.76%) 14 (82.35%) 
> 100 ml 0 (0%) 0 (0%) 9 (100%) 
Total 13 (26%) 13 (26%) 24 (48%) 
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Table –VIII Comparison between clinical severity scoring  and serial  
mean acetylcholinesterase values 
  
POP Score 
Categories 
AchE 
levels 
Mean 
Std. 
Error 
95% Confidence 
Interval 
p value 
by 
ANOVA 
Lower 
Bound 
Upper 
Bound 
Mild 
Day 1 4671.636 348.444 3966.249 5377.024 
<0.001 
Day 2 4527.091 363.951 3790.311 5263.871 
Day 3 5521.364 392.422 4726.946 6315.781 
Discharge 5600.636 387.338 4816.512 6384.761 
Moderate 
Day 1 3128.818 348.444 2423.430 3834.206 
<0.001 
Day 2 2704.455 363.951 1967.674 3441.235 
Day 3 4045.091 392.422 3250.673 4839.508 
Discharge 5190.455 387.338 4406.330 5974.579 
Severe 
Day 1 620.263 265.126 83.543 1156.983 
<0.001 
Day 2 645.684 276.925 85.079 1206.290 
Day 3 1037.000 298.589 432.539 1641.461 
Discharge 1905.947 294.720 1309.318 2502.577 
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There is a clear correlation found between clinical severity POP scoring 
and Mean serial acetylcholinesterase values. Since patients with severe POP 
scoring had reduced mean acetylcholinesterase values from admission till 
discharge /  death. 
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Table –IX Comparison between clinical severity scoring  and serial mean 
ABG  PH 
  
POP Score 
Categories 
ABG pH Mean 
Std. 
Error 
95% Confidence 
Interval p value by 
ANOVA Lower 
Bound 
Upper 
Bound 
Mild Day 1 7.414 0.029 7.354 7.474 
<0.001 
Day 2 7.412 0.023 7.365 7.459 
Day 3 7.398 0.017 7.363 7.433 
Discharge 7.398 0.016 7.365 7.431 
Moderate Day 1 7.401 0.028 7.344 7.458 
<0.001 
Day 2 7.401 0.022 7.356 7.446 
Day 3 7.396 0.017 7.363 7.430 
Discharge 7.404 0.016 7.372 7.435 
Severe Day 1 7.433 0.021 7.390 7.476 
<0.001 
Day 2 7.435 0.017 7.401 7.469 
Day 3 7.426 0.013 7.401 7.452 
Discharge 7.418 0.012 7.394 7.442 
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As clinical  severity scoring  of opc poisoning  is associated with 
reducing pH values in serial monitoring  , since (p<0.001). As patients mean 
PH with severe scoring has highest  values from day 1 till discharge /death , as 
most of them had alkalosis. Those with moderate scoring had mixed values 
with both acidotic and alkalosis  Those with mild scoring had normal PH . 
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Table- X  
Clinical severity POP scoring and serial mean bicarbonate levels 
 
POP Score 
Categories 
HCO3 Mean 
Std. 
Error 
95% Confidence 
Interval 
p value 
by 
ANOVA 
Lower 
Bound 
Upper 
Bound 
Mild 
Day 1 24.900 1.247 22.374 27.426 
<0.001 
Day 2 25.000 1.178 22.614 27.386 
Day 3 25.000 1.161 22.647 27.353 
Discharge 24.500 0.828 22.822 26.178 
Moderate 
Day 1 22.182 1.189 19.773 24.590 
<0.001 
Day 2 22.727 1.123 20.452 25.002 
Day 3 23.091 1.107 20.848 25.334 
Discharge 23.818 0.790 22.218 25.418 
Severe 
Day 1 23.158 0.904 21.325 24.990 
<0.001 
Day 2 23.947 0.854 22.216 25.678 
Day 3 24.000 0.842 22.293 25.707 
Discharge 23.263 0.601 22.046 24.481 
 
There is a clear correlation between clinical POP severity scoring  and  
Serial mean bicarbonate values with  negative correlation. Patients with any of 
clinical score had normal bicarbonate values since most of them had respiratory 
paralysis and most  are either respiratory alkalosis and acidosis. 
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Table- XI Comparison between clinical POP severity scoring and serial  
mean  ABG PaCO2 values 
POP Score 
Categories 
PaCO2 Mean 
Std. 
Error 
95% Confidence 
Interval 
p value 
by 
ANOVA 
Lower 
Bound 
Upper 
Bound 
Mild 
Day 1 41.200 6.368 28.298 54.102 
<0.001 
Day 2 40.400 14.922 10.166 70.634 
Day 3 39.900 2.275 35.291 44.509 
Discharge 39.500 2.029 35.389 43.611 
Moderate 
Day 1 40.455 6.071 28.153 52.756 
<0.001 
Day 2 66.909 14.227 38.082 95.736 
Day 3 39.455 2.169 35.060 43.849 
Discharge 38.455 1.935 34.535 42.374 
Severe 
Day 1 43.632 4.620 34.271 52.992 
<0.001 
Day 2 38.842 10.825 16.908 60.776 
Day 3 39.158 1.650 35.814 42.501 
Discharge 39.316 1.472 36.333 42.298 
There is a correlation found between clinical severity scoring and serial 
mean PaCO2 values. 
Since patients with  severe POP scoring had increased PaCO2 values as 
in respiratory acidosis , as well as respiratory alkalosis which is predominantly 
seen in our study population with reduced PaO2 and PaCO2. 
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Table – XII Comparison between clinical POP  severity scoring  and  ABG 
interpretation in our study population 
ABG 
Interpretaion 
POP Score categories P value by Chi 
sq test Mild Moderate Severe 
Normal 7 (53.84%) 3 (23.07%) 0 (0%) 
<0.001 
Metabolic 
Acidosis 
2 (15.38%) 1 (7.69%) 0 (0%) 
Metabolic 
Alkalosis 
2 (15.38%) 3 (23.07%) 0 (0%) 
Respiratory 
Acidosis 
1 (7.69%) 3 (23.07%) 7 (29.16%) 
Repsiatory 
Alkalosis 
1 (7.69%) 3 (23.07%) 17 (70.83%) 
Total 13 (100%) 13 (100%) 24 (100%) 
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Graph – VI showing clinical severity scoring and ABG interpretation 
 
 
 
Opc compounds cause multiple pulmonary complication like respiratory 
muscle paralysis by its nicotinic action, increased pulmonary seretions by its 
muscarnic actions, leading to aspiration pneumonitis and pneumonia that can 
be ventilator associated. 
Thus patients those with severe clinical scoring had only respiratory acid 
base disturbances with predominating respiratory alkalosis due to reduced 
partial pressure of oxygen and co2 wash out, next to which comes respiratory 
acidosis with co2 retention. 
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Table –XIII Comparison between clinical POP severity scoring and 
atropine dosing / duration of hospital stay/ventiloation  duration 
 
 
 
POP score N Mean 
Std. 
Deviation 
95% Confidence 
Interval for 
Mean 
p value 
by 
ANOVA Lower 
Bound 
Upper 
Bound 
Atropine 
Dose 
Mild 13 4.538 3.4548 2.451 6.626 
<0.001 
Moderate 13 9.462 13.0934 1.549 17.374 
Severe 24 21.708 7.6697 18.470 24.947 
Total 50 14.060 11.4382 10.809 17.311 
Duration 
of 
ventilation 
days 
Mild 13 .308 .7511 -.146 .762 
0.001 
Moderate 13 1.385 3.9484 -1.001 3.771 
Severe 24 4.625 4.0947 2.896 6.354 
Total 50 2.660 3.9518 1.537 3.783 
Hospital 
Stay Days 
Mild 13 3.08 .862 2.56 3.60 
0.067 
Moderate 13 5.85 4.598 3.07 8.62 
Severe 24 6.96 5.835 4.49 9.42 
Total 50 5.66 4.893 4.27 7.05 
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There is a correlation between  clinical severity POP scoring and 
atropine dosing ,  duration of hospital days , duration of ventilation. As clinical 
severity increases the  need for atropine dosage increase, duration of ventilation 
days (p ≤ 0.001). 
Duration of hospital stay increases with clinical severity . 
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Table –XIV Comparison between clinical severity POP scoring  and 
Intermediate syndrome  & Graph -VII 
 
POP Score 
categories 
Intermediate syndrome 
Total 
Fisher exact  
p value Yes No 
Mild 0 (0%) 13 (100%) 13 (100%) 
0.0034 
Moderate 2 (15.38%) 11 (84.61%) 13 (100%) 
Severe 9 (37.5%) 15 (62.5%) 24 (100%) 
Total 11 (22%) 39 (78%) 50 (100%) 
 
 
Clinical severity POP scoring  correlates with intermediate syndrome 
37.5 % of  patients going for intermediate syndrome belong to severe  category 
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Graph-VII Comparison between clinical severity POP scoring  and 
Intermediate syndrome  & Graph -VII 
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Table –XV Comparison between ventilator requirement and clinical 
severity scoring &Graph -VIII 
 
POP Score 
categories 
Ventilator 
Total 
p value by 
Chi sq test Yes No 
Mild 2 (15.38%) 11 (84.61%) 13 (100%) 
<0.001 
Moderate 2 (15.38%) 11 (84.61%) 13 (100%) 
Severe 24 (100%) 0 (0%) 24 (100%) 
Total 28 (56%) 22 (44%) 50 (100%) 
 
  
57 
 
 
 
Graph VIII showing correlation between ventilator requirement and 
clinical severity scoring, as severity increases ventilation is required 
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Table - XVI Comparison between clinical severity scoring and 
complications 
 
POP Score 
categories 
Complications 
Total 
p value by 
Chi sq test Yes No 
Mild 2 (15.38%) 11 (84.61%) 13 (100%) 
<0.001 
Moderate 1 (7.69%) 12 (92.3%) 13 (100%) 
Severe 22 (91.66%) 2 (8.33%) 24 (100%) 
Total 25 (50%) 25 (50%) 50 (100%) 
 
There is a correlation between clinical severity POP  scoring with  
complications like  respiratory paralysis , arrhythmias , intermediate syndrome  
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Graph-IX  showing  correlation between complications of opc poisoning 
with clinical POP scoring 
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TABLE-XVII  
COMPARISON BETWEEN CLINICAL OUTCOME AND CLINICAL 
SCORING  
 
POP Score 
categories 
Outcome 
Total χ2(0.05) 
Death Discharged 
Mild 0 (0%) 13 (100%) 13 (100%) 
<0.001 
Moderate 0 (0%) 13 (100%) 13 (100%) 
Severe 20 (83.33%) 4 (16.66%) 24 (100%) 
Total 20 (40%) 30 (60%) 50 (100%) 
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Graph X showing clinical outcome and clinical severity scoring 
 
 
 
 
 
  
62 
 
Table- XVIII Comparison between acid base disorders in  ABG 
interpretation and intermediate syndrome  
 
ABG 
Interpretaion 
Intermediate syndrome 
Total 
P VALUE 
BY Chi sq 
test 
Yes No 
Normal 0 (0%) 10 (100%) 10 (100%) 
<0.001 
Metabolic 
Acidosis 
0 (0%) 3 (100%) 3 (100%) 
Metabolic 
Alkalosis 
0 (0%) 5 (100%) 5 (100%) 
Respiratory 
Acidosis 
5 (45.45%) 6 (54.54%) 11 (100%) 
Repsiatory 
Alkalosis 
6 (28.57%) 15 (71.42%) 21 (100%) 
Total 11 (22%) 39 (78%) 50 (100%) 
 
 
Patients with respiratory acid base disorders rather than metabolic are 
prone for intermediate syndrome.  
Although patients with intermediate syndrome most of them had 
respiratory alkalosis and respiratory acidosis. 
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GRAPH-XI  SHOWING  CORRELATION  BETWEEN  
INTERMEDIATE SYNDROME  AND  INTERPRETATION  OF 
ARTERIAL BLOOD GAS ANALYSIS. 
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TABLE-XIX COMPARISON BETWEEN   
VENTILATOR REQUIREMENT AND ABG INTERPRETATION 
 
ABG 
Interpretaion 
Ventilator 
Total 
P VALUE 
BY Chi sq 
test 
Yes No 
Normal 0 (0%) 10 (100%) 10(100%) 
<0.001 
Metabolic 
Acidosis 
0 (0%) 3 (100%) 3 (100%) 
Metabolic 
Alkalosis 
0 (0%) 5 (100%) 5 (100%) 
Respiratory 
Acidosis 
10 (90.9%) 1 (9.09%) 11 (100%) 
Repsiatory 
Alkalosis 
17 (80.95%) 4 (19.04%) 21 (100%) 
Total 28 (56%) 22 (44%) 50 (100%) 
 
Ventilator requirement is not assessed with ABG interpretation, instead 
the need for intubation and mechanical ventilation is assessed clinically. 
Most of the patients whom required ventilator had either respiratory 
alkalosis predominantly due to PaCO2 wash out and reduced partial pressure of 
oxygen or respiratory acidosis due to co2 retention.  
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Graph-XII  
Showing correlation between ventilator requirement and ABG 
interpretation 
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Table-XX  
Comparing complications associated with opc compounds and ABG 
interpretation 
ABG 
Interpretaion 
Complications 
Total 
P VALUE 
BY Chi sq 
test 
Yes No 
Normal 1 (10%) 9 (90%) <0.001 
<0.001 
Metabolic 
Acidosis 
0 (0%) 3 (100%) 3 (100%) 
Metabolic 
Alkalosis 
0 (0%) 5 (100%) 5 (100%) 
Respiratory 
Acidosis 
8 (72.72%) 3 (27.27%) 11 (100%) 
Repsiatory 
Alkalosis 
16 (76.19%) 5 (23.8%) 21 (100%) 
Total 25 (50%) 25 (50%) 50 (100%) 
 
Complications like respiratory paralysis, arrhythmias, intermediate 
syndrome are commonly associated with respiratory alkalosis or acidosis. 
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Graph-XIII showing correlation between complications due to opc 
poisoning and acid base disturbances in ABG analysis 
 
 
 
 
 
 
 
 
68 
 
Table-XXI  
Comparison between clinical outcome and acid base  disturbances in ABG 
Interpretation 
 
Mortality is associated with respiratory paralysis which are associated 
with  either respiratory alkalosis predominantly  and  acidosis  to some extent. 
 
 
 
  
ABG 
Interpretaion 
Outcome 
Total 
P VALUE 
BY Chi sq 
test Death Discharged 
Normal 0 (0%) 10 (100%) <0.001 
<0.001 
Metabolic 
Acidosis 0 (0%) 3 (100%) 3 (100%) 
Metabolic 
Alkalosis 0 (0%) 5 (100%) 5 (100%) 
Respiratory 
Acidosis 5 (45.45%) 6 (54.54%) 11 (100%) 
Repsiatory 
Alkalosis 15 (71.42%) 6 (28.57%) 21 (100%) 
Total 20 (40%) 30 (60%) 50 (100%) 
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Graph-XIV showing correlation between clinical outcome and ABG 
interpretation 
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DISCUSSION 
Comprehensive analysis of 50 cases of acute Organophosphorus 
poisoning. 
Epidemiology of Organophosphorus poisoining 
AGE DISTRIBUTION : 
In this series, the organophosphorus poisoning was most prevalent in the 
age group 21 – 30 years. 28 cases out of 50 were below the age of 40 years. 
Pyar Ali et al observed the mean age group of 28.6 ±9.8 years from Karachi. 
Another study from Karachi by AftabTurab et al observed the age group 
of  15– 20 years (44.77%)  was predominant. Murat Sungur et al from Turkey 
observed the mean age group as 30 ±15 years. Karalliedde L., Senanayake N.et 
al of Srilanka documented 91% of their cases were under the age of 30. 
Malik et al from Kashmir, revealed the predominant population affected 
were under the age of 25. In Mangalore, Karnataka, India, the most common 
age group to be affected  between 20 – 30 (36.6%). KuntalBattacharyya et al of 
Kolkata reported the mean age of 25.5 years.  
This young age group affected by exposure and also in terms of 
procurement and productivity. This study throw light on the target age group 
by improving  the management protocol and decreasing the mortality. 
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SEX DISTRIBUTION : 
In our series, males (n=36) dominated the study population. Malik et al 
observation of 122 cases in Kashmir valley (females n=114, males n=50),  In 
Mangalore and Srilanka the pattern of case series with male predominance. 
S.Shivakumar and K.Raghavan et al of Tamilnadu reported 165 cases of  
organophosphorus73 poisoning and sex distribution was with male 
predominance. KuntalBattacharya et al from Kolkata showed male 
predominance. 
In Southern part of India, males are actively involved in spraying 
fertilizers and pesticides. 
 
OCCUPATION DISTRIBUTION : 
In our case series, 14 out of 50 (28 %) were agriculturists. Non 
agriculturist were exposed more to organophosphorus compounds with the 
suicidal intent. Agriculturist, also accidentally exposed due to the spraying in 
the field. In Kashmir Valley, two third of the population who had exposed were 
engaged in apple orchard. 
 
ROUTE OF EXPOSURE : 
In our series, most of the cases occurred due to ingestion (100%) and No 
one had accidental inhalation (0%). 
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FREQUENCY OF EXPOSED : 
The common organophosphorus compounds abused in our series are 
chlorpyrifos and Monochrotophos . Kuntal Bhattacharyya et al also escribed 
the most frequent compound as Chlorpyrifos(38.1%). 
CLINICAL SEVERITY SCORE : 
Peradeniya organophosphorous poisoning scale as a predictor of 
respiratory failure and mortality in organophosphorous poisoning  was a study 
conducted by Pradeep et al published at 2017  which included 50 patients  and 
6 parameters in clinical scoring with incidence of respiratory failure in  
23 (46%) patients and death in around 66.6% individuals of severe scoring.  
Correlation of serum cholinesterase level, clinical score at presentation 
and severity of organophosphorous poisoning  by S Rehiman et al Studied  
50 patients using peradenya organophosphorous compounds in  Which severity 
directly  correlated  with serum cholinesterase level. 
Jiung –Hsiun Liu  et al made a study on  acid base interpretation can be 
the predictor of outcome among patients with acute organophosphate poisoning 
before hospitalisation. 
In  a  9 year  retrospective study of 82 patients, they  were grouped into 
4- without acidosis, metabolic acidosis, respiratory acidosisand mixed acidosi 
Found that mortality rate of op poisoned patients with metabolic acidosis was 
25% and respiratory acidosis was 50 % 
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LABORATORY CORRELATES : 
SERUM ACETYLCHOLINESTERASE : 
Serum acetylcholinesterase levels are monitored from admission till 
discharge or death in patients with acute organophosphorous compound 
poisoning. In our study, serum cholinesterase levels are  correlated with the  
clinical severity by Peradyneia organophosphorous poisoning scale, prolonged 
duration of hospital stay, prolonged duration of mechanical ventilation, 
increased need for atropine dosage. It also correlated with the incidence of 
complications and outcome. Thus with the morbidity and mortality it had the 
pattern of negative correlation. 
 
ARTERIAL BLOOD GAS ANALYSIS : 
Eventhough arterial blood gas analysis has multiple parameters 
including PH, PaCO2, PaO2,HCO3- , Na+ , K+ , Cl- , Anion gap , So2.  
But for  interpretation of simple acid base disorders only PH, HCO3- , 
PaCO2 is enough and most common acid base disturbances seen among our 
study is Respiratory alkalosis and next to which is Respiratory acidosis 
probably due to respiratory paralysis , central apnea  and pulmonary secretions. 
In many studies metabolic acidosis which is proven fatal, but in our 
study both Metabolic acidosis and alkalosis can be managed, but the respiratory 
component which needs mechanical ventilation is proven fatal. 
  
  
 
 
 
CONCLUSION 
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CONCLUSION 
 
1. Peradeniya Organophosphorus Poisoning scale is a much needed clinical    
assessment scale for categorising the severity of cases with acute   
organophosphorus poisoning. 
2. Serum acetylcholinesterase levels which correlates with clinical Severity 
scoring has been proved by many studies to provide aggressive  
treatment. 
3. Arterial blood gas estimation eventhough not available in many 
peripheral hospitals has to be done to interpret the acid base disturbances 
and treat accordingly and as soon as possible. Since respiratory acidosis 
as well as alkalosis can be managed by mechanical ventilation and 
metabolic acidosis can be treated with bicarbonate. 
 
 
  
  
 
 
 
 
SUMMARY 
 
 
 
 
 
75 
 
SUMMARY 
 
Case fatality rate comes around 60% in developing countries where 
there are many changes in treatment protocol and research activities. 
Henceforth  we proceeded  with  a study including 50 patients correlating 
arterial blood gas analysis with clinical severity peradeniya  
organophosphorous poisoning score and serum acetylcholinesterase levels  at 
our toxicology unit, poison research centre, Institute of Toxicology, Rajiv 
Gandhi Government General Hospital, Chennai. 
There is a direct correlation between clinical severity POP scoring and 
serum acetylcholinesterase values from admission till discharge/ death and 
correlation between clinical severity and ABG interpretation in which many of  
patient with severe POP scoring and  less acetylcholinesterase values  had  
respiratory alkalosis and respiratory acidosis  
In our study population of 50 patients around 10(20%)  of the 
individuals  who presented with mild scoring had  normal ABG values. 
Around 21(42%) individuals who had  respiratory alkalosis  at  
presentation with severe 17 (70%) clinical scoring on admission due to 
respiratory paralysis.  
In patients with respiratory acidosis around 11(22%)  individuals  had 
severe Clinical scoring 7 (29%) on  admission till discharge Probably this 
severity that is correlating with respiratory acid base disorders are due to 
pulmonary complications like respiratory paralysis and pulmonary secretions, 
central apnea, and bronchospasm  leading on to co2 wash out, decreased partial 
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pressure of oxygen  and co2 retention is seriously fatal however with poper and 
adequate ventilation some of them  managed to survive.     
In our study population of 50 individuals around  6% of  them had  
metabolic acidosis in which all of them had better outcome no mortality , as it 
can be treated with IV sodabicarbonate 
Around  10% of individuals had  metabolic alkalosis in their arterial 
blood gas Interpretation with almost all of them had a better prognosis, without 
any complications like respiratory failure with need for mechanical ventilation,  
intermediate syndrome, with no mortality similar to metabolic acidosis 
22 % of patients of total population went in for  respiratory acidosis that 
can be interpreted in ABG probably due pulmonary secretions , central apnea 
Leading to CO2 retention in the pulmonary alveoli and other complications , 
intermediate syndrome, need for mechanical ventilation for intubation and 
mechanical vemntilation done, eventough around  45 % of them had poor 
prognosis and outcome. 
In our study around 42 % of individuals , the majority had  respiratory  
Alkalosis probably due to decrease respiratory drive , respiratory paralysis 
leading to decreased partial pressure of oxygen in blood due to poor diffusion 
across the alveoli and  CO2 washout with increased complications, 
intermediate syndrome  and poor prognosis and outcome. 
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RECOMMENDATIONS  
 
Research into the correlation between op compound poisoning and acid 
base alteration and cause for respiratory acidosis and respiratory alkalosis in 
organophosphorus poisoning is worth to be considered. 
The role of arterial blood gas status  in organophosphorus  poisoning  
needs to be studied since the exact cause of alteration in blood PH, PCO2 and 
bicarbonate values are unclear. 
Many studies around worldwide had questioned about the use of 
oximes, hence, a randomized control trial comparing the current WHO 
recommended guidelines with placebo is required to evaluate the need of 
pralidoxime in acute organophosphorus poisoning. 
Use of fresh frozen plasma therapy,organophosphorus hydrolases 
derived  from pseudomonas, Butrylcholinesterase replacement therapy,  extra 
corporeal clearance, alpha 2 recptor adrenergic agonist to improve survival and 
reduce complications need to be studied. 
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LIMITATIONS OF  THE STUDY 
Since  our  study  has been conducted in only in 50 individuals and  also 
included patients who had consumed opc poisoning in very mild doses and 
least Toxic compounds. Hence around 20 % of individuals in our study had 
normal arterial blood gas values. It could not be applied for the entire  
population, the treatment should be individualised. 
Although in many studies metabolic acidosis is prove fatal , we got only 
6 % with metabolic acidosis and all of them had good outcome Arterial blood 
gas gives good parameters  to know about acid base disorders But it could not 
be used everywhere and anywhere because of its cost and availability. 
Since many of the centers analyse clinically the need for intubation and  
mechanical ventilation. 
But as for as concerned arterial blood gas analysis is essential to know 
about the acid base status and correct accordingly and intervene as soon as  
possible.  
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PATIENT CONSENT FORM 
Study Detail : “CORRELATION OF ARTERIAL BLOOD GAS 
ANALYSIS IN PREDICTIG OUTCOME OF  
ACUTE ORGANOPHOSPHOROUS COMPOUND 
POISONING”  
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
                                               Patient may check (√) these boxes 
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and doubts 
have been answered to my complete satisfaction. 
 
 
❏
 
I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving reason, without my legal rights being 
affected. ❏ 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will not 
need my permission to look at my health records, both in respect of current 
study and any further research that may be conducted in relation to it, even if 
I withdraw from the study I agree to this access. 
 
I understand that my identity will not be revealed in any information released to 
third parties or published, unless as required under the law. I agree not to restrict 
the use of any data or results that arise from this study.                                                                                                                             
❏
 
 
 
 
❏
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I agree to take part in the above study and to comply with the                              
instructions given during the study and faithfully cooperate with the study team 
and to immediately inform the study staff if I suffer from any    deterioration in 
my health or well being or any unexpected or unusual symptoms. 
 
❏
 
 
I hereby give  consent to participate in this study. ❏ 
I hereby give permission to undergo detailed clinical examination and blood 
investigations as required ❏ 
 
 
   
Signature of investigator    Signature/Thumb impression                                             
 
 
Study investigator Name:    Patient name and address 
 
Dr.S.MUKIL 
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PROFORMA 
NAME                                            : 
AGE/SEX                                       : 
IP No.                                             : 
OCCUPATION         :                                     
II.POISONING 
 COMPOUND   
 AMOUNT   
TIME OF CONSUMPTION   
  
III.SYMPTOMS: 
 VOMITING   
 LOOSE STOOLS   
 SALIVATION/LACRIMATION/SWEATING   
 DYSPNOEA   
 BLURRING OF VISION   
 SEIZURES   
 LOSS OF CONSCIOUSNESS   
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IV.PAST HISTORY: 
DIABETES MELLITUS   
HYPERTENSION   
BRONCHIAL ASTHMA/COPD   
TUBERCULOSIS   
  
V.PERSONAL HISTORY: 
SMOKING   
ALCOHOLISM   
 
VI.SYSTEMIC EXAMINATION: 
 CVS   
 RS   
 ABDOMEN   
 CNS   
  
 VII.INVESTIGATIONS: 
CBC   
LFT   
 RFT   
 SERUM ELECTROLYTES   
 RBS   
 URINE(R/E)   
 ECG   
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ANNEXURE IV 
PERADENIYA  ORGANOPHOSPHORUS  SCALE 
  
PARAMETERS 0 1 2 SCORE 
PUPIL SIZE ≥2 mm <2mm PINPOINT  
RESPIRATORY RATE <20/min ≥20/min 
≥20/min with 
central 
cyanosis 
 
HEART RATE >60/min 41-60/min <40/min  
FASCICULATION None 
Present 
Generalised/continuous 
Both 
generalised 
and 
continuous 
 
LEVEL OF 
CONSCIOUSNESS 
Conscious 
and 
rationale 
Impaired response to  
verbal commands 
No response to 
verbal 
commands 
 
SEIZURE 
 
Absent Present -  
GRADE 
 
Mild(0-3) Moderate(4-7) Severe(8-11)  
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ANNEXURE V 
SERIAL ESTIMATION OF ARTERIAL BLOOD GAS ANALYSIS 
  
 
 
DAY 1 DAY  2 DAY 3 ON DISCHARGE 
 
CLINICAL SCORING 
        
 
SERUM 
ACETYLCHOLINESTERASE 
        
 
ARTERIAL BLOOD GAS 
ANALYSIS 
 
        
 
ATROPINE REQUIREMENT 
         - 
COMPLICATIONS 
IF ANY 
         - 
   
DURATION OF HOSPITAL STAY 
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INFORMATION SHEET 
We are conducting a study on “CORRELATION OF ARTERIAL 
BLOOD GAS ANALYSIS IN PREDICTIG OUTCOME OF ACUTE 
ORGANOPHOSPHOROUS COMPOUND POISONING” among patients 
attending Rajiv Gandhi Government General Hospital, Chennai and for that 
your specimen may be valuable to us. 
 
The purpose of this study Acute organophosphorus compound poisoning 
is very common among patients admitted to casualty in our hospitals. Methods 
to diagnose, monitor and prognosticate are non specific. There is a need to 
develope the parameters other than clinical in these patients for the better 
outcome. 
 
We are selecting certain cases and if you are found eligible, we may be 
using your blood samples to do certain tests. 
 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment. 
 
Signature of Investigator     Signature of Participant 
 
Date : 
Place : 
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1 50 M Non-Agri Chlorpyrifos 150 6 Severe Severe Moderate Mild 548 1535 3455 3788 7.47 26 30 7.43 24 40 7.4 24 40 7.36 24 38 RESPIRATORY ALKALOSIS 5 NO YES 2 YES 5 Discharge
2 41 M Agri Monocrotphos 60 3 Moderate Mild Mild Mild 2585 2585 2589 4532 7.35 22 39 7.35 22 40 7.35 23 42 7.36 24 42 NORMAL 6 NO NO 0 NO 4 Discharge
3 43 M Agri Endosulphan 120 4 Severe Severe Severe Severe 254 342 332 217 7.28 24 60 7.36 26 42 7.34 28 58 7.35 28 58 RESPIRATORY ACIDOSIS 22 NO YES 5 YES 5 Death
4 25 M Non-Agri Parathion 80 3 Severe Severe Moderate Mild 185 1490 2455 2788 7.49 24 28 7.48 22 30 7.46 20 34 7.44 20 36 RESPIRATORY ALKALOSIS 20 YES YES 10 YES 15 Discharge
5 30 M Non-Agri Monocrotphos 50 8 Severe Severe Severe Severe 190 455 533 585 7.29 20 62 7.31 22 55 7.33 24 50 7.34 28 48 RESPIRATORY ACIDOSIS 16 NO YES 11 YES 11 Death
6 21 M Non-Agri Monocrotphos 80 6 Severe Severe Severe Severe 245 546 566 568 7.47 24 28 7.46 24 32 7.47 22 30 7.46 24 28 RESPIRATORY ALKALOSIS 18 NO YES 4 YES 7 Death
7 28 M Non-Agri Temephos 50 3 Mild Mild Mild Mild 5666 5112 5223 5444 7.41 25 39 7.4 24 40 7.4 25 42 7.4 25 42 NORMAL 3 NO NO 0 NO 3 DIscharge
8 35 F Non-Agri Chlorpyrifos 90 2 Severe Severe Severe Severe 2554 3448 3223 2114 7.48 22 26 7.46 22 32 7.47 24 33 7.47 26 35 RESPIRATORY ALKALOSIS 16 NO YES 5 YES 6 Death
9 18 M Non-Agri Chlorpyrifos 15 16 Moderate Mild Mild Mild 3455 468 4577 7.42 25 40 7.42 25 40 7.42 25 40 NORMAL 2 NO NO 0 NO 2 Discharge
10 75 M Agri Demeton 150 8 Severe Severe Severe 398 458 286 7.29 24 102 7.3 38 74 7.3 38 74 RESPIRATORY ACIDOSIS 18 NO YES 2 NO 2 Death
11 30 M Non-Agri Monocrotphos 100 4 Severe Severe Severe Severe 558 446 345 358 7.47 20 28 7.47 24 30 7.47 22 32 7.46 20 34 RESPIRATORY ALKALOSIS 28 NO YES 5 NO 7 Death
12 27 M Non-Agri Malathion 50 14 Moderate Mild Mild Mild 3557 4557 5343 5444 7.28 17 35 7.32 22 32 7.35 23 34 7.36 24 36 METABOLIC ACIDOSIS 6 NO NO 0 NO 5 Discharge
13 35 M Non-Agri Isofluorphate 80 7 Severe Severe Severe Severe 678 626 556 546 7.48 24 28 7.47 18 30 7.46 22 32 7.43 23 36 RESPIRATORY ALKALOSIS 26 NO YES 5 YES 9 Death
14 24 F Non-Agri Bromophos 60 10 Mild Mild Mild Mild 4566 4568 4578 4558 7.48 34 40 7.47 32 40 7.45 30 38 7.44 26 36 METABOLIC ALKALOSIS 6 NO NO 0 NO 4 Discharge
15 37 M Non-Agri Diazinon 30 8 Moderate Mild Mild Mild 4556 4556 5667 5668 7.32 18 32 7.34 20 335 7.35 22 36 7.36 22 37 RESPIRATORY ACIDOSIS 8 NO NO 0 NO 5 Discharge
16 30 M Non-Agri Endosulphan 150 12 Severe Severe 350 350 7.53 20 112 7.53 20 112 RESPIRATORY ALKALOSIS 20 NO YES 1 YES 1 Death
17 45 M Agri Phorate 30 4 Moderate Moderat
e
Mild Mild 843 950 1224 4065 7.47 28 44 7.46 26 40 7.45 26 40 7.45 26 40 METABOLIC ALKALOSIS 6 No No 0 No 7 Discharge
18 25 F Non-Agri Monocrotphos 150 16 Severe Severe 158 158 7.52 26 108 7.52 26 108 RESPIRATORY ALKALOSIS 20 No Yes 1 Yes 1 Death
19 48 M Agri Malathion 15 3 Mild Mild Mild Mild 4536 5420 6228 6228 7.34 20 36 7.36 22 37 7.36 22 37 7.36 22 37 METABOLIC ACIDOSIS 3 No No 0 No 3 Discharge
20 35 M Non-Agri Temephos 20 4 Mild Mild Mild 5684 6632 6632 7.4 23 38 7.4 24 40 7.4 24 40 NORMAL 2 No No 0 No 2 Discharge
21 21 F Non-Agri Profenofos 100 8 Severe Severe Severe Severe 224 180 324 2335 7.28 28 115 7.3 32 69 7.32 36 58 7.33 24 55 RESPIRATORY ACIDOSIS 32 Yes Yes 9 Yes 15 Death
22 28 M Non-Agri Monocrotphos 100 7 Severe Severe Severe Severe 368 254 324 3454 7.52 22 21 7.49 18 29 7.47 20 35 7.46 20 35 RESPIRATORY ALKALOSIS 24 Yes Yes 3 Yes 7 Death
23 48 M Agri Primiphos 50 2 Moderate Mild Mild 2987 3336 4853 7.43 26 40 7.44 25 41 7.44 25 41 NORMAL 4 No No 0 No 2 Discharge
24 70 M Agri Chlorpyrifos 150 6 Severe Severe 358 358 7.49 22 41 7.49 22 28 RESPIRATORY ALKALOSIS 16 No Yes 1 Yes 1 Death
25 21 F Non-Agri Endosulphan 25 2 Mild Mild Mild Mild 3647 4688 5536 5536 7.45 25 39 7.44 24 38 7.43 23 38 7.43 23 38 NORMAL 3 No No 0 No 3 Discharge
26 38 F Non-Agri Dimethoate 30 3 Mild Mild Mild Mild 5985 3882 5221 5232 7.33 20 35 7.35 22 37 7.37 24 39 7.37 24 39 METABOLIC ACIDOSIS 3 No No 0 No 4 Discharge
27 38 M Non-Agri Triazophos 25 2 Moderate Moderat
e
Mild Mild 4165 3662 5688 6345 7.49 30 43 7.47 28 45 7.44 25 40 7.43 24 39 METABOLIC ALKALOSIS 5 No No 0 No 6 Discharge
28 50 M  Agri Diazinon 100 6 Severe Severe Severe Severe 287 195 346 366 7.49 26 31 7.49 26 31 7.47 25 32 7.47 27 35 RESPIRATORY ALKALOSIS 18 Yes Yes 2 Yes 5 Death
29 41 M Non-Agri Quinalphos 25 3 Mild Mild Mild Mild 7835 7235 7647 7647 7.38 22 37 7.39 23 40 7.39 23 40 NORMAL 3 No No 0 No 2 Discharge
30 29 F Non-Agri Chlorpyrifos 15 1 Mild Mild Mild Mild 5432 5910 6341 6341 7.44 26 45 7.44 25 42 7.43 26 42 7.43 26 42 NORMAL 3 No No 0 No 3 Discharge
31 20 M Non-Agri Monocrotphos 150 5 Severe Severe Severe Severe 389 165 1242 1563 7.52 25 30 7.49 28 36 7.47 26 38 7.33 18 40 RESPIRATORY ALKALOSIS 26 Yes Yes 2 Yes 6 Death
32 60 F Agri Dicrotophos 75 8 Moderate Moderat
e
Moderate Mild 2180 1672 2656 5839 7.29 15 40 7.31 18 35 7.33 20 39 7.38 24 38 RESPIRATORY ACIDOSIS 52 Yes Yes 14 Yes 20 Discharge
33 37 F Non-Agri Monocrotphos 100 3 Severe Severe Severe Severe 1894 759 560 580 7.51 20 28 7.5 20 30 7.49 18 32 7.49 18 32 RESPIRATORY ALKALOSIS 25 No Yes 3 Yes 3 Death
34 34 F Non-Agri Diazinon 50 5 Moderate Mild Mild Mild 4376 3852 5645 6479 7.29 18 71 7.31 24 58 7.33 22 48 7.37 24 38 RESPIRATORY ACIDOSIS 14 Yes Yes 4 No 8 Discharge
35 26 F Non-Agri Phorate 100 5 Severe Severe Severe Severe 687 416 1558 1853 7.53 21 27 7.49 20 29 7.47 18 32 7.38 23 38 RESPIRATORY ALKALOSIS 18 Yes Yes 3 Yes 7 Death
36 35 M Agri Diazinon 25 2 Mild Mild Mild Mild 4751 3674 6790 6790 7.52 30 45 7.49 28 45 7.38 25 38 7.38 25 38 METABOLIC ALKALOSIS 2 No No 0 No 3 Discharge
37 18 M Non-Agri Ethion 30 2 Moderate Mild Mild Mild 4569 3357 4798 4798 7.51 32 44 7.48 28 43 7.45 26 41 7.45 26 41 METABOLIC ALKALOSIS 4 No No 0 No 3 Discharge
38 60 M Agri Quinalphos 50 5 Moderate Moderat
e
Mild Mild 2705 942 3456 4521 7.46 20 34 7.44 22 37 7.44 22 37 7.44 22 37 RESPIRATORY ALKALOSIS 6 No No 0 No 5 Discharge
39 58 M  Non-Agri Phosphomidon 75 4 Severe Severe Severe Severe 586 295 1458 2628 7.55 21 30 7.54 18 30 7.42 18 31 7.51 18 28 RESPIRATORY ALKALOSIS 10 Yes Yes 2 Yes 6 Death
40 22 F Non-Agri Phosphomidon 100 3 Severe Severe Severe Mild 369 158 348 4984 7.29 25 91 7.33 29 56 7.34 31 54 7.41 27 46 RESPIRATORY ACIDOSIS 42 Yes Yes 18 Yes 26 Discharge
41 70 F Agri Fenthion 25 2 Mild Mild Mild 1586 995 2864 7.44 26 41 7.44 26 41 7.44 26 41 NORMAL 12 No Yes 2 Yes 2 Discharge
42 30 M Non-Agri Dimethoate 75 5 Severe Severe Moderate Mild 964 391 1248 4835 7.31 24 88 7.33 28 58 7.39 30 48 7.4 26 41 RESPIRATORY ACIDOSIS 34 Yes Yes 9 Yes 14 Discharge
43 14 M Non-Agri Phorate 50 4 Moderate Moderat
e
Mild Mild 751 258 1548 3513 7.47 22 33 7.47 18 37 7.43 20 38 7.4 21 36 RESPIRATORY ALKALOSIS 4 No No 0 No 5 Discharge
44 50 M Agri Monocrotphos 150 10 Severe Severe Severe Severe 239 176 248 898 7.52 22 31 7.55 28 32 7.53 22 30 7.53 22 30 RESPIRATORY ALKALOSIS 25 No Yes 3 Yes 3 Death
45 38 M Non-Agri Dichlorphos 30 2 Mild Mild Mild Mild 3584 3395 4216 4216 7.38 22 37 7.38 23 39 7.39 24 41 7.39 24 41 NORMAL 4 No No 0 No 3 Discharge
46 17 M Non-Agri Malathion 25 3 Mild Mild Mild Mild 2230 1675 3445 4105 7.33 23 62 7.35 27 48 7.37 26 44 7.38 25 42 RESPIRATORY ACIDOSIS 12 No Yes 2 Yes 5 Discharge
47 30 M Non-Agri Monocrotphos 150 4 Severe Severe 364 364 7.57 25 28 7.57 25 28 RESPIRATORY ALKALOSIS 20 No Yes 1 Yes 1 Death
48 42 M Agri Ethion 30 3 Moderate Moderat
e
Mild Mild 4130 3358 5882 5891 7.48 22 30 7.46 22 34 7.44 25 39 7.44 25 39 RESPIRATORY ALKALOSIS 6 No No 0 No 4 Discharge
49 22 M Non-Agri Triazophos 25 2 Mild Mild Mild Mild 3156 4239 5510 5510 7.46 24 34 7.44 23 38 7.4 25 40 7.4 25 40 RESPIRATORY ALKALOSIS 3 No No 0 No 3 Discharge
50 20 F Non-Agri Chlorpyrifos 100 22 Severe Severe Severe Severe 566 391 582 1753 7.28 22 47 7.31 26 47 7.33 26 45 7.32 26 54 RESPIRATORY ACIDOSIS 22 No Yes 4 Yes 4 Death
